The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

Inclusion Criteria: 1. Men or women ≥18 years of age 2. Screened negative for COVID-19 symptoms at time of consent, as per institutional policy and as applicable for the duration of the COVID-19 pandemic 3. Diagnosed with stages I-IV primary NSCLC, MM, TNBC or RCC 4. Plan to be treated at a partner cancer site with a checkpoint inhibitor (anti-PD-1, anti-PD-L1, or anti-CTLA-4) as a single agent or in combination with another checkpoint inhibitor or other treatment agent or modality (e.g., targeted therapy, chemotherapy, surgery, radiation, etc.) in accordance with FDA-labeled use of the agent 5. Able to provide informed consent and answer study questionnaires in either English or Spanish 6. Able to provide stool specimens for research purposes Exclusion Criteria: 1. Mental incapacity 2. Incarcerated individuals 3. Pregnancy (by self-report of pregnancy status) 4. Experiencing active brain metastasis/metastases 5. Treatment with checkpoint inhibitor in off-label capacity or through a clinical/interventional trial 6. Active participation in an immuno-oncology clinical/interventional trial or pharma-sponsored observational study